Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

OBJECTIVE: Pembrolizumab has benefited patients with advanced non-small-cell lung cancer (NSCLC) with a programmed death-ligand (PD-L)1 high expression, but little information is available regarding its safety for patients with interstitial lung disease (ILD). The aim of this study was to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Tetsuo, Kuroki, Tsuguko, Hayama, Nami, Shiraishi, Yuka, Amano, Hiroyuki, Nakamura, Makoto, Hirano, Satoshi, Tabeta, Hiroshi, Nakamura, Sukeyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492129/
https://www.ncbi.nlm.nih.gov/pubmed/32389949
http://dx.doi.org/10.2169/internalmedicine.4552-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492129/
https://www.ncbi.nlm.nih.gov/pubmed/32389949
http://dx.doi.org/10.2169/internalmedicine.4552-20

Ejemplares similares